Drug Database
NA

naproxen (naproxen, Verex / naproxen, Biovail)

✓ Approved

Bausch Health Companies Inc. · PTGS1 · Small Molecule

What is naproxen?

naproxen is a small molecule developed by Bausch Health Companies Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Namesnaproxen, Verex, naproxen, Biovail
CompanyBausch Health Companies Inc.
Drug ClassSmall Molecule
Molecular TargetPTGS1, PTGS2
RouteOral (PO)
StatusApproved

Mechanism of Action

Molecular Targets

naproxen acts on 2 molecular targets:

PTGS1prostaglandin-endoperoxide synthase 1 (COX3, PCOX1)
PTGS2prostaglandin-endoperoxide synthase 2 (GRIPGHS, hCox-2)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

naproxen is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Musculoskeletal and connective tissue disordersMusculoskeletal pain✓ Approved

Related Research Articles

PubMedJournal of environmental sciences (China)2026-07-25

Gallic acid enhanced Cu(II)/H2O2 system for efficient degradation of naproxen: Insights into redox cycling and radical generation.

Chen Zhenbin Z, Yuan Yiwei Y, Wan Guodong G, Wang Zongping Z et al.

Previous studies have demonstrated that aqueous copper ions (Cu(II)) can activate hydrogen peroxide (H2O2) to generate hydroxyl radicals (HO•) for oxidative degradation of pharmaceuticals and personal care products (PPCPs). However, the treatment efficiency of this process is constrained by the kinetically limited reduction of Cu(Ⅱ) to Cu(I). In this study, introducing gallic acid (GA) into the Cu(II)/H2O2 system significantly enhanced the degradation efficiency of the model pharmaceutical compound naproxen (NPX) across a broad pH range (5.0-9.0). Under neutral conditions (initial pH 7.0, unadjusted), the GA/Cu(II)/H2O2 system achieved a high NPX degradation ratio of 92.0 % within 30 min, representing a 9.89-fold enhancement compared to the Cu(II)/H2O2 system alone. Mechanisms investigation revealed the simultaneous generation of Cu(III) and HO•, with quantitative analysis confirming HO• as the predominant reactive species. The modified performance is attributed to the formation of Cu(I)-GA complexes, which not only facilitate the Cu(II)/Cu(I) redox cycle but also lower the redox potential of the Cu(II)/Cu(I) couple, thereby promoting H2O2 activation. The system demonstrates excellent applicability for degrading diverse PPCPs, exhibits strong resistance to most common water matrix interferences, and maintains effective NPX removal and dissolved organic matter removal in real water samples including secondary water and lake water.

PubMedCarbohydrate polymers2026-07-24

Probing the moisture-induced drug recrystallization in hydroxypropyl methylcellulose-based amorphous solid dispersions.

Suresh Arvindh Seshadri AS, Van Brempt Famke F, Abrahmsén-Alami Susanna S, Larsson Anette A

Hydroxypropyl methylcellulose (HPMC), a widely used cellulose derivative, plays a central role in stabilizing drug-containing amorphous solid dispersions (ASDs), by inhibiting the drug recrystallization. However, the moisture sorption behavior of HPMC can compromise the physical stability of ASDs under humid conditions. This study examines how humidity, drug loading, storage time, and spatial location within the ASD together influence the recrystallization behavior of a model drug (naproxen) in HPMC-based ASDs prepared via hot melt extrusion. We hypothesized that moisture induced drug recrystallization is governed primarily by the water sorption characteristics of HPMC. To investigate moisture induced drug recrystallization, extrudates were stored for 14 days at 75% and 98% RH. All formulations remained fully amorphous (>99.5%) at 75% RH, whereas significant recrystallization occurred at 98% RH. Notably, recrystallization initiated at the extrudate surface, reflecting moisture driven structural gradients within the polymer matrix. These results establish a structure-property relationship linking HPMC hydration and increased chain mobility to drug recrystallization, providing a mechanistic insight relevant for designing robust moisture-resistant cellulose derivatives-based drug delivery systems.

PubMedJournal of medical toxicology : official journal of the American College of Medical Toxicology2026-07-22

An Emerging Synthetic Opioid in the Drug Supply: A Case of Opioid Overdose with Biological Confirmation of Cychlorphine.

Kusko Rebecca R, Liss David D, House Stacey L SL, House Serena B SB et al.

Cychlorphine (also referred to as N-propionitrile chlorphine) is a non-fentanyl synthetic opioid that has been linked to the illicit drug supply and fatal overdoses in the United States since 2024. A female in her 20s presented to the emergency department (ED) following ingestion of what the patient reported was alprazolam. Unresponsiveness and respiratory depression prompted 6 mg of intranasal naloxone administration by emergency medical services prior to arrival to the ED. Comprehensive toxicological testing of serum revealed the presence of cychlorphine. Additional substances found were bromazolam, carboxy-THC, acetaminophen, caffeine, citalopram, cotinine, naloxone, naproxen, nicotine, and trazodone and its metabolite. This rare case of clinical signs of opioid overdose with cychlorphine detected is the first to provide direct evidence linking a non-fatal overdose to cychlorphine exposure. A naloxone responsive opioid toxidrome is described with an opiate and fentanyl negative initial urine drug screen. Advanced analytical techniques were required to identify the presence of cychlorphine.

PubMedNeurochemistry international2026-07-21

Early treatment with naproxen alters hippocampal metabolites in the TgF344-AD rat model of Alzheimer's disease.

Fowler Caitlin F CF, Osipyan Elena E, Devenyi Gabriel A GA, Madularu Dan D et al.

Alzheimer's disease (AD) is characterized by the appearance of brain pathology decades prior to clinical symptoms. The pre-symptomatic phase of AD provides opportunity for early detection and intervention. One early intervention that has been proposed is the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as naproxen. However, evidence suggests that effects of naproxen intervention differ with stage of the disease, and the optimal intervention time is not clear. Accordingly, in this study, we investigated the impact of the timing of naproxen treatment in a rat model of AD. We used the TgF344-AD rat model of AD which develops characteristic pathological features of human AD, including abundant amyloid plaque pathology, astrogliosis, and microgliosis by 6 months of age, and neurofibrillary tangles and neuronal loss by 16 months of age. We examined the effects of naproxen treatment beginning at 1, 4, and 10 months of age in transgenic (Tg) animals and their wild-type (WT) littermates. We used longitudinal in vivo magnetic resonance spectroscopy (MRS) to study the impact of naproxen treatment on hippocampus neurochemistry. Previous studies have used MRS to non-invasively characterize the trajectory of altered hippocampal neurochemistry across the lifespan in the TgF344-AD rat model. In the current study, we employed MRS at 4, 10, and 16 months, i.e. prior to or after the appearance of amyloidosis and gliosis (6 months) and tau pathology (16 months), respectively, in Tg animals. Naproxen treatment altered neurochemistry in Tg animals only if administered beginning at 1 or 4 months of age, mitigating an otherwise observed increase in total choline and decrease in taurine. A more subtle effect was observed on the otherwise-expected increase in myo-inositol. These results highlight the possibility that earlier naproxen intervention could have distinct neurochemical effects compared to delayed treatment, though mechanistic implications remain to be clarified. Moreover, these findings support the use of MRS as a useful non-invasive method of monitoring treatment-related changes in neurochemistry in transgenic animal models.

PubMedWater research2026-07-21

Sunlight-driven activation of periodate by excited triplet humic acid for efficient microcontaminant abatement.

Zhang Bin B, Lu Qiuling Q, Zhang Wenjun W, Lu Haonan H et al.

Humic acid (HA) may inhibit the degradation of contaminants by quenching reactive species in some traditional advanced oxidation processes (AOPs). However, our study found that HA can remarkably enhance the degradation of contaminants by the sunlight-activated periodate (PI) system in practical applications. Herein, a HA-boosted sunlight-activated PI system for contaminant degradation was systematically investigated. The results showed that 2 mgC/L HA increased the degradation efficiency of naproxen (NAP) by about 2.4-fold in the sunlight/PI system. Increased HA or PI concentration enhanced NAP degradation by the sunlight/PI/HA system. Quencher, fluorescence and nitrogen experiments proved that hydroxyl radical (HO·) and ozone (O3) were the main reactive species for the degradation of NAP. Radical probe and O3 experiments confirmed that the increase of pH decreased the quantum yield of PI photolysis, resulting in the decrease of average O3 concentration and the steady-state concentration of HO·, thereby lowering the degradation of NAP. The contributions of HO· and O3 to NAP degradation were determined to be from 65.4% to 81.1% and from 19.3% to 28.1% at pH 4.0-9.0, respectively. The situation of PI decline in different systems proved that the triplet excited state of HA (3HA*) rather than HA·- was the key intermediate species for the accelerated activation of PI, and PI was eventually converted into iodate. The accelerated activation of PI with increasing HA concentration was attributed to the elevated steady-state concentration of 3HA*. Additionally, the applicability of the sunlight/PI/HA system was verified by the degradation of seven different micropollutants. Suwannee River natural organic matter (SRNOM) was also demonstrated to exhibit similar enhancing effects on PI activation as HA under sunlight exposure. Cl- and HCO3- inhibited the degradation of NAP in view of the conversion of HO· into chlorine-containing and carbonate radicals. This work provides a novel insight into improving the solar-photoactivated PI process for water treatment.

PubMedChemMedChem2026-07-16

Computer-Aided Drug Design, Synthesis, and In Vitro Safety Evaluation of Carprofen Analogs for Novel Alzheimer's Disease Therapeutics.

Acosta-Guzmán Paola P, Bedoya-Malagón Daniel D, Mercado-Coy Luisa L, Morantes Sandra Johanna SJ et al.

Nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, naproxen, and indomethacin, have reduced amyloid beta (Aβ) levels and improved cognitive function in mouse models of Alzheimer's disease (AD). The objective of the current research is to evaluate different NSAIDs using computer-aided drug design (CADD) to explore their potential as new treatments for AD. CADD is an advanced technique for designing biologically active molecules and involves two primary approaches: structure-based virtual screening and ligand-based virtual screening. After identifying the NSAID with the highest affinity for amyloid Aβ1-42 fibrils (PDB 2BEG), we designed analogs through bioisosteric modifications. Twenty derivatives were created, and two carprofen analogs with the most promising properties were synthesized, yielding 75% success with compound A-1 and 70% with compound A-2. These analogs exhibited lower predicted IC50 values (1.57 μM) and more negative interaction energies (-6.43 and -6.67 kcal/mol for A-1 and A-2, respectively) compared to carprofen. Safety evaluations in L929 cells indicated that these compounds were safe at concentrations of 40 µM. In conclusion, two carprofen analogs were successfully designed and synthesized, demonstrating higher affinity for the amyloid Aβ1-42 fibrils, better-predicted IC50 values than carprofen, and safety in the L929 in vitro assay.

+7494 more articles available with a free account

Sign up free to view all articles →

Ask about naproxen